Delgocitinib ointment shows efficacy for atopic dermatitis in phase 3 trial

  • Nakagawa H & al.
  • J Am Acad Dermatol
  • 3 Feb 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Delgocitinib 0.5% ointment is associated with clinical efficacy and good safety in patients with moderate to severe atopic dermatitis (AD), according to results from a phase 3 trial.

Why this matters

  • Novel topical treatment options with a good efficacy-safety profile are needed for AD.

Key results

  • Delgocitinib was associated with a greater least-squares mean percentage change from baseline compared with vehicle at 4 weeks: −44.3% vs 1.7% (P<.001>
  • Compared with vehicle, delgocitinib was associated with higher rates of patients achieving ≥50% improvement on:
    • Modified Eczema Area and Severity Index (mEASI-50): 51.9% vs 11.5% (P<.001>
    • mEASI-75: 26.4% vs 5.8% (P<.01>
  • 50.6% of patients who received delgocitinib experienced adverse events (44.2% mild, 6.5% moderate).
    • The most common adverse event was nasopharyngitis (19.5%).

Study design

  • 158 patients with moderate to severe AD were randomly assigned to receive delgocitinib 0.5% ointment (n=106) or vehicle (n=52), and followed for efficacy and safety outcomes.
  • Funding: Japan Tobacco Inc.

Limitations

  • Short trial duration.